ISO 10993 Biocompatibility
Consulting for Medical Devices
Bring the actual device, draft file, reviewer question, or planned change. MedDev Advisory will identify whether the practical next step is a BEP, BER, TRA, focused review, or wider remediation for ISO 10993, EU MDR, FDA 510(k), or India / CDSCO work.
Typical High-Priority Projects
Where teams usually need help fast
Aligned with the frameworks reviewers actually scrutinize
Built for teams that need a clear submission path, not generic template writing
I typically support teams that already have a device, a regulatory target, and a concrete documentation problem to solve.
MedTech Startups
Founders and first-time submission teams that need a defensible BEP, BER, or biocompatibility plan from scratch.
RA/QA Teams
Regulatory and quality teams that need expert support on endpoint strategy, waiver justification, or document review before submission.
Manufacturers Updating Legacy Files
Companies upgrading older BEPs and BERs to align with ISO 10993-1:2025, lifecycle framing, and current reviewer expectations.
Submission Consultants
Consultants and cross-functional teams that need specialist ISO 10993 input for FDA, EU MDR, or deficiency-response packages.
Best when these details are already clear
The clearer the starting inputs are, the faster I can assess scope, identify likely documentation gaps, and recommend the next practical step.
When those basics are defined upfront, scope review is usually faster and the work can start with fewer back-and-forth questions.
Devices I Work With
If your device touches, implants into, or communicates with the human body — I can prepare the biological evaluation documentation.
Implantable, Orthopaedic & Dental Devices
Long-term implants, bone-contacting fixation systems, and oral-contact devices requiring rigorous endpoint strategy, material evidence, and biological-risk reasoning. See the implantable-device support scope.
Catheters, Tubing & Cardiovascular Devices
Direct or indirect blood-contact and fluid-path devices where shafts, hubs, connectors, coatings, adhesives, and lubricants must be assessed together. Read the catheter and fluid-path guide.
Wound Care & Skin-Contact Devices
Dressings, wearable interfaces, and other surface-contacting devices where intact skin, breached tissue, released substances, adhesives, and repeated wear change the evidence question. Read the wound-dressing guide.
Diagnostic, IVD-Adjacent & Ophthalmic Devices
Patient-contacting biosensors, imaging probes, electrodes, and ocular devices where the interface—not only the instrument label—defines the biological-evaluation scope. See the biosensor support page.
Not sure if your device fits? Send me a brief description — I'll confirm scope and timeline within 24 hours, no obligation.
ISO 10993 & Regulatory Services
Core ISO 10993 drafting, gap analysis, and submission remediation for teams preparing CE Mark, FDA, and India pathways.
Biological Evaluation Plan (BEP)
ISO 10993-1:2018/2025 endpoint strategy. Indicative working window: 3–5 business days after complete inputs, confirmed in the proposal.
View dedicated BEP service page Already have a draft? Use the BEP review service Need a no-new-testing rationale? View test-waiver support ISO 10993-1:2025Biological Evaluation Report (BER)
Literature evaluation, existing-data assessment, and risk-based conclusions. Indicative working window: 5–7 business days after complete inputs, confirmed in the proposal.
View dedicated BER service page Already have a draft? Use the BER review service ISO 10993-1:2025Toxicological Risk Assessment (TRA)
AET/TTC calculations per ISO 10993-17 and ISO 10993-18 for extractables and leachables.
Read how TRA supports modern biological evaluation ISO 10993-17/18ISO 10993-1:2025 Gap Analysis
Assess existing BEP/BER documentation against the updated 2025 requirements. Identify and resolve gaps.
View dedicated gap-analysis page 2025 UpdateMaterial Change Biocompatibility Assessment
Structured change-impact review for supplier, formulation, coating, sterilization, process, packaging, and design changes.
View dedicated material-change page Change ControlImplantable Device Biocompatibility Support
ISO 10993 support for implantable devices, implantable biosensors, long-term endpoint strategy, and file remediation.
View dedicated implantable-device page High-risk devicesBiocompatibility Documentation Review
Best first step when a BEP, BER, TRA, or summary section already exists and needs a specialist check before submission.
Use the review as your first step Pre-submissionEU MDR Technical File — Biocompatibility Section
Annex I GSPR §10 compliant documentation for CE Mark technical file submission.
View dedicated EU MDR support page EU MDRNotified Body Query Response
Point-by-point remediation for BEP, BER, waiver, materials, and Annex I gaps raised during CE Mark review.
View dedicated notified body response page CE Mark RemediationFDA 510(k) Biocompatibility Section
Uses FDA's final September 2023 biocompatibility guidance together with current recognition records and applicable device-specific sources.
View dedicated FDA support page Responding to an FDA request? Read the remediation guide FDA 510(k)CDSCO Strategy & Documentation Support
India pathway planning, documentation readiness, and biocompatibility-linked submission strategy. Indian manufacturers and export-oriented startups can also start with the broader quality-readiness vertical.
India quality and biocompatibility readiness View dedicated CDSCO support page India / CDSCOBiocompatibility Documentation Review
Best first step when a draft file already exists and the team needs to know whether it is usable, weak in key places, or headed toward reviewer friction.
See how the review is packaged Pre-submissionIndia / CDSCO support and related work such as CER, PMCF/PMS, and scientific writing are available where they directly support the regulatory documentation strategy. If your team already has a draft file, the review offer is usually the cleanest first step.
Biological-Evaluation Work Grounded in Research
My scientific background spans biomaterials, cell-response research and implantable biosensors, including hands-on cytotoxicity and ISO 10993-aligned biological-endpoint work. That experience helps me connect the scientific question behind each endpoint with the evidence and rationale needed in a traceable biological-evaluation file.
Marie Skłodowska-Curie Research Experience
Hands-on cytotoxicity, oxidative stress, biomaterial–cell interaction, and ISO 10993-aligned biocompatibility testing at INSERM U1026 Biotis in Bordeaux, within the Marie Skłodowska-Curie ImplantSens research network on implantable electrochemical biosensors.
ISO 10993-1:2025 Practice Focus
Focused work with the 2025 revision — lifecycle approach, explicit benefit-risk determination, test-waiver justification, and legacy BEP/BER gap analysis. I build clear, traceable reviewer-facing documentation.
Implantable-Device Research Experience
Research experience in implantable electrochemical biosensors, including within the EU-funded ImplantSens network — a high-complexity context involving long-term contact, device–tissue interfaces, material evidence and biological-risk reasoning.
Fast, Structured Delivery
Indicative planning ranges are 3–5 business days for a BEP and 5–7 business days for a BER after receipt of complete inputs. Exact scope, schedule, formats, and revision terms are confirmed in writing before work starts.
International Research & Cross-Market Perspective
Research experience in India, France, Germany and Sweden broadens the scientific perspective brought to each engagement. Regulatory support is scoped separately to the applicable EU, UK, US, or Asia-Pacific requirements, evidence package, and current primary sources. Fluent in English; working knowledge of French.
Arvind Rathore
ISO 10993 Biocompatibility Consultant
CDSCO Medical Device Biological Safety Submission Playbook
Build India-focused biological-safety evidence into a controlled Device Master File while keeping route, applicant, site, device-state and specialist responsibilities distinct.
Version 1.1.0 is the corrected current edition. It incorporates the final G.S.R. 743(E) and 744(E) amendment stack while preserving version 1.0.1 as a historical correction record.
Browse all five current professional booksFrom Inquiry to Delivered Documentation
A clear, structured process from first contact to submission-ready documentation.
Initial Scoping Call
We review your device, contact category, current documentation, and submission timeline so I can confirm fit and define the most practical next step.
Scope & Proposal
I define the documentation scope, endpoint strategy, and deliverables. Clear timeline and fixed price quote.
Documentation Drafting
I prepare scientifically grounded BEP/BER/TRA documentation aligned to your regulatory target (EU MDR or FDA).
Review & Delivery
You review the draft, provide feedback, and I finalize. Delivered in Word and PDF. One revision included.
Representative File and Remediation Patterns
These non-identifying patterns illustrate typical documentation problems and delivery approaches. A pattern may consolidate recurring features from more than one engagement; it is not a client testimonial, approval claim, or promise of an identical result.
Implantable Biosensor — CE Mark Submission
Representative pattern for a long-term implantable electrochemical sensor: establish the complete biological-effect strategy in the BEP, then carry the same device, chemistry, evidence, uncertainty, and risk logic into the BER for notified-body review.
Vascular Catheter — FDA Additional Information Response
Representative pattern for an FDA additional-information request involving an incomplete cytotoxicity-extract rationale and missing polymer-hub chemistry: triage the cited gaps, rebuild the chemistry and exposure chain, and prepare endpoint-specific response rationales for reviewer follow-up.
Wound Dressing — Legacy BER Gap Analysis
Representative pattern for an existing BER prepared under the 2018 edition: identify the material gaps against the 2025 framework, preserve still-applicable evidence, and strengthen lifecycle, uncertainty, and benefit-risk reasoning only where the file needs it.
Frameworks & Standards I Work With
Biological Evaluation Series
- Part 1: Evaluation & Testing (2018 & 2025)
- Part 5: Cytotoxicity
- Part 10: Sensitization & Irritation
- Part 17: Toxicological Risk Assessment
- Part 18: Chemical Characterization
EU MDR 2017/745
- Annex I — GSPR §10 Biocompatibility
- Annex II — Technical Documentation
- Annex III — PMS Documentation
- CER (MEDDEV 2.7/1 Rev.4)
- PMCF Plan & Report
FDA 510(k) & PMA
- FDA final ISO 10993-1 guidance (September 2023)
- 510(k) Biocompatibility Section
- De Novo Submissions
- PMA Applications
- FDA Query Responses
Quality & Risk Management
- ISO 13485:2016 QMS
- ISO 14971:2019 Risk Management
- Risk-Based Biocompatibility Strategy
- Design Control Documentation
- CAPA Documentation
How to Hire Me
Three clear engagement paths. If a draft file already exists, start with the review offer. If not, pick the drafting or remediation path that matches the real problem.
Submission Gap Review
You already have a BEP, BER, TRA, or summary section and need the fastest credible first step
- Expert review of your existing BEP, BER, or TRA
- Written gap memo with specific findings
- Recommended fixes per ISO 10993-1:2025
- Regulatory alignment check (EU MDR or FDA)
- One follow-up call to discuss findings
Full Documentation Draft
You need a complete BEP, BER, or TRA written from scratch
- Full BEP or BER drafted from device brief
- All applicable ISO 10993 endpoints addressed
- Scientifically justified test waivers where applicable
- Structured for EU MDR Annex I §10 or FDA's final September 2023 guidance, as applicable
- Delivered in Word + PDF, one revision included
Deficiency Remediation
FDA or notified body flagged your documentation — you need a targeted, fast response
- Analysis of FDA/NB deficiency letter or query
- Point-by-point written response document
- Updated BEP/BER sections where required
- Scientific justification for each deficiency
- Submission-ready format, one revision included
Share your situation and I will tell you the likely scope, the fastest practical path forward, and whether the project is a fit.
Questions teams ask before they start a scope
The fastest way to move forward is to clarify whether you need a new BEP, a document review, or a cleanup of a file that already exists.
Do we need all testing complete before a BEP is written?
No. A strong BEP usually comes first. It sets the endpoint strategy, the evidence path, and where existing data or waivers may be enough.
View BEP serviceWhat makes a BEP look generic to a reviewer?
Usually vague device framing, copied endpoint tables, and waiver logic that is asserted without a clear scientific basis tied to the actual device.
Read the BEP mistakes articleWhat if we already have a draft BEP, BER, or TRA?
That is often a review problem, not a rewrite problem. A fast gap review can show whether the file needs selective remediation or deeper restructuring.
Start with a gap reviewWhat information helps scope the work fastest?
Device description, contact type and duration, materials, current documents, and the target pathway. With that, the next step is usually clear quickly.
Send a project briefHow quickly will we know the right next step?
Usually once the device context and current file state are reviewed, it becomes clear whether the right move is a BEP, a BER review, a gap review, or a broader consulting scope.
Share the current file stateWhat if we are not sure whether we need a BEP, BER, or TRA?
That is common. The first job is often to classify the problem correctly so you do not spend time rewriting the wrong document or ordering the wrong next step.
Use a gap review to decideWhat is MedDev Advisory?
MedDev Advisory is an independent ISO 10993 biocompatibility consulting practice led by Arvind Rathore for medical-device documentation and reviewer-facing file work.
Read about MedDev AdvisoryWho founded MedDev Advisory?
MedDev Advisory was founded and is led by Arvind Rathore, a medical-device biocompatibility consultant with biomaterials, ISO 10993, and implantable biosensor research experience.
View Arvind's backgroundWhat services does MedDev Advisory provide?
The core work covers ISO 10993 biological evaluation strategy, BEP, BER, TRA, EU MDR biocompatibility sections, FDA 510(k) support, and selected India / CDSCO documentation.
View service optionsIs MedDev Advisory affiliated with ISO, FDA, EU authorities, CDSCO, or notified bodies?
No. MedDev Advisory is an independent consulting practice and is not affiliated with, endorsed by, or approved by ISO, FDA, EU authorities, notified bodies, CDSCO, or the Government of India.
Read the disclaimerUseful starting points: the ISO 10993 strategy guide, the practical ISO 10993-1:2025 gap checklist, and the chemical characterization support page for chemistry-driven files.
Latest Insights
Expert articles and regulatory updates on ISO 10993, EU MDR, FDA, and India topics — written by a practising consultant, not a template library.
Catheter and Fluid-Path Biocompatibility
When shafts, lumens, hubs, connectors, valves, adhesives, and lubricants create direct or indirect patient-exposure questions.
Reusable-Instrument Biocompatibility After Reprocessing
How cleaning, disinfection, sterilization, and repeated use can affect residues, surfaces, representative states, and biological evidence.
Wearable Electrode and Skin-Contact Biocompatibility
A practical guide to adhesives, hydrogels, conductive materials, repeated wear, and the limits of FDA intact-skin policy.
Preparing a Biological Evaluation?
Request a Scoping Review.
Whether you're preparing an initial BEP, responding to a notified body query, or updating legacy documentation to ISO 10993-1:2025, send the project context and I will outline the likely scope, priorities, and next step before any engagement.
I respond within 24 hours on business days